Liver Cancer Drug Market To Triple By 2014; MNCs Will Take Lead
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sales of hepatocellular carcinoma drugs in China will nearly triple from $53 million in 2009 to $144 million in 2014, a new research report from Decision Resources found
You may also be interested in...
China Likely To Delay Drug Price Cuts Until Next Year: Good News Or Bad?
SHANGHAI - The National Development and Reform Commission, China's leading economic regulatory body, is revising a drug price control plan that was issued in June for public feedback after receiving industry-led objections to some proposals
China's Health System Reforms Are Opening Gates To Creating Gigantic Pharmacy Chains, Says One Would-be Titan
BEIJING - The first phase of Beijing's healthcare reforms, centered on expanding medical facilities across the hinterland and extending insurance coverage to rural residents, is creating massive opportunities for drug retailers to form giant chain stores to march through and occupy the Chinese countryside, say the leaders of would-be giant BioPharm Asia
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).